Search research articles
Contact Us
Filters
Showing results (11-20 of 436) with videos related to
Page
of 44
Sort By:
Health Affairs Scholar
|
April 22, 2026
Cost-effectiveness thresholds used in the United States vs most favored nations
Hanxuan Yu, Peter J Neumann, David D Kim, et al.
International Journal of Technology Assessment in Health Care
|
April 29, 2020
Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?
Xue Feng, David D Kim, Joshua T Cohen, et al.
The American Journal of Managed Care
|
October 18, 2019
Variation in US private health plans' coverage of orphan drugs
James D Chambers, Ari D Panzer, David D Kim, et al.
Medical Care
|
August 29, 2022
Effect of the 2012 US Preventive Services Task Force Recommendations on Prostate-Specific Antigen Screening in a Medicare Advantage Population
Yingying Zhu, Benjamin Koethe, Daniel A Ollendorf, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 22, 2022
The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies
Siyu Ma, Natalia Olchanski, Joshua T Cohen, et al.
Pharmacoeconomics
|
July 23, 2020
Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018
David D Kim, Madison C Silver, Natalia Kunst, et al.
Pharmacoeconomics
|
October 22, 2020
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974-2018
David D Kim, Madison C Silver, Natalia Kunst, et al.
Health Affairs (Project Hope)
|
July 10, 2018
Specialty Drug Coverage Varies Across Commercial Health Plans In The US
James D Chambers, David D Kim, Elle F Pope, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
May 16, 2017
The influence of time horizon on results of cost-effectiveness analyses
David D Kim, Colby L Wilkinson, Elle F Pope, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 1, 2021
Toward Better Data Dashboards for US Drug Value Assessments
Peter J Neumann
Page
of 44
Search research articles
Search
Showing results (11-20 of 436) with videos related to
Sort By:
Page
of 44
Health Affairs Scholar
|
April 22, 2026
Cost-effectiveness thresholds used in the United States vs most favored nations
Hanxuan Yu, Peter J Neumann, David D Kim, et al.
International Journal of Technology Assessment in Health Care
|
April 29, 2020
Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?
Xue Feng, David D Kim, Joshua T Cohen, et al.
The American Journal of Managed Care
|
October 18, 2019
Variation in US private health plans' coverage of orphan drugs
James D Chambers, Ari D Panzer, David D Kim, et al.
Medical Care
|
August 29, 2022
Effect of the 2012 US Preventive Services Task Force Recommendations on Prostate-Specific Antigen Screening in a Medicare Advantage Population
Yingying Zhu, Benjamin Koethe, Daniel A Ollendorf, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 22, 2022
The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies
Siyu Ma, Natalia Olchanski, Joshua T Cohen, et al.
Pharmacoeconomics
|
July 23, 2020
Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018
David D Kim, Madison C Silver, Natalia Kunst, et al.
Pharmacoeconomics
|
October 22, 2020
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974-2018
David D Kim, Madison C Silver, Natalia Kunst, et al.
Health Affairs (Project Hope)
|
July 10, 2018
Specialty Drug Coverage Varies Across Commercial Health Plans In The US
James D Chambers, David D Kim, Elle F Pope, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
May 16, 2017
The influence of time horizon on results of cost-effectiveness analyses
David D Kim, Colby L Wilkinson, Elle F Pope, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 1, 2021
Toward Better Data Dashboards for US Drug Value Assessments
Peter J Neumann
Page
of 44